ArticlePloS one2015
Prevalence of Cognitive Impairment in Recently Diagnosed Type 2 Diabetes Patients: Are Chronic Inflammatory Diseases Responsible for Cognitive Decline?
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Prevalence, risk factors, and early prediction of cognitive impairment in patients with diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Risk factors for cognitive decline in type 2 diabetes mellitus adults: a systematic review and meta-analysis.Molecular and cellular biochemistry · 2025Pooled it
- Prevalence and Predictors of Cognitive Decline Among Diabetes Mellitus Patients Attending Jinja Regional Referral Hospital: A Cross-Sectional Study in Eastern Uganda.Health science reports · 2025Article
- Functional connectivity alterations in the thalamus among patients with bronchial asthma.Frontiers in neurology · 2024Article
- Incretin Therapy and Insulin Signaling: Therapeutic Targets for Diabetes And Associated Dementia.Current diabetes reviews · 2024Review
- Neurocognitive impairment and its associated factors among patients with diabetes mellitus who have follow up at referral hospital in Northwest, Ethiopia.Frontiers in endocrinology · 2024Article
- Prevalence of Psychiatric Morbidity and Cognitive Impairment among Patients Attending the Rural Noncommunicable Disease Clinic.Journal of neurosciences in rural practice · 2020Article
- The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction.European journal of nutrition · 2020Review
- Biomarkers for cognitive decline in patients with diabetes mellitus: evidence from clinical studies.Oncotarget · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the prevalence of cognitive impairment (CI) among patients recently diagnosed with type 2 diabetes (RDD) and to identify any relationships between CI and RDD comorbidities.
methodsOne thousand seven hundred twelve patients with RDD participated in a cross-sectional study. The patients' sociodemographic and clinical data were registered.
resultsThe sample population had an average age of 51 ± 11 years, and 63.26% of the patients were female. CI was diagnosed in 38 patients (2.2%) and was more common among both females (2.8% vs. 1.3%, p = 0.063) and the elderly (0% at an age ≤ 30 years vs. 10.4% at an age > 70 years, p = 0.0001). Rheumatoid arthritis (present in 15.8% vs. absent in 2.1%) and asthma (13% vs. 2.1%) correlated significantly with CI based on the results of our logistic regression analysis.
conclusionAge, female gender, rheumatoid arthritis and asthma are risk factors for CI in the setting of RDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.